Fig. 5.

In vitro validation of the inhibitory effect of the 13-amino acid peptide inhibitor (13AApi) on severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike receptor-binding domain (RBD) was examined with an enzyme-linked immunosorbent assay (ELISA) test kit. A The image reproduced from the BP Biosciences ELISA kit demonstrates the steps in the assay. B Percent inhibitory activity of the 13AApi at the indicated concentrations on the binding of SARS-CoV-2 spike RBD to angiotensin-converting enzyme 2 (ACE2). The plotted graph represents the mean of three biological replicates